Physician profile
Daniel T Mccall
NPI 1871694646
$1,000.47
in general payments reported to CMS, 2019-2025
10 companies · $94.15 in 2025
The $94.15 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.43 · 2021: $39.86 · 2022: $294 · 2023: $334 · 2024: $160 · 2025: $94.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $605.00 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $115.39 | 2022-2024 | |
| Amgen INC. | $59.24 | 2019-2025 | Tepezza, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.12 | 2019 | |
| Rgh Enterprises LLC | $40.08 | 2025 | |
| Lilly USA, LLC | $39.29 | 2023 | Lyumjev, Jardiance, Baqsimi |
| Horizon Therapeutics Plc | $33.77 | 2022-2023 | Tepezza |
| Medtronic, INC. | $29.36 | 2022-2023 | Minimed 780g |
| Insulet Corporation | $21.73 | 2019 | |
| Beta Bionics, INC. | $16.49 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mccall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.